Effects of Azithromycin as an Adjunct to Scaling and Root Planning in the Treatment of Periodontitis
Periodontitis

About this trial
This is an interventional treatment trial for Periodontitis focused on measuring Azithromycin, M1 macrophages, M2 macrophages, Macrophages-targeted therapy, Periodontitis
Eligibility Criteria
Inclusion criteria for healthy volunteers:
- Presence of more than 20 teeth (for each tooth, the probing pocket depth ≤3 mm
- Absence of clinical gingival inflammation at intact or reduced periodontium
Inclusion Criteria:
- The presence of at least 15 natural teeth, at least 10 sites with the periodontal pocket depth (PPD) ≥4 mm, and/or clinical attachment loss of ≥4 mm at the same site, and satisfactory general health
Exclusion Criteria:
- Taking antibiotics or anti-inflammatory medications within the previous 3 months
- Periodontal therapy within the previous 6 months
- Purulent exudation from periodontal pockets
- Pregnancy or breastfeeding
- Severe, uncontrolled (decompensated) diseases of the internal organs, or neuropsychiatric disorders
- Other conditions that determined the patient's inability to understand the nature and possible consequences of the study
Sites / Locations
- Department of Postgraduate Education for Dentists of Poltava State Medical University,
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Other
Az group
SRP group
H group
Periodontitis patients, who underwent scaling and root planning (SRP) as one-stage full-mouth disinfection procedure and additionally received oral azithromycin ("Health" Pharmaceutical Company, Kharkiv, Ukraine) in a dose of 500 mg q.d. for 7 days, then 500 mg q.w. for the next 3 weeks
Periodontitis patients who underwent scaling and root planning (SRP) as one-stage full-mouth disinfection procedure.
Reference group. 25 healthy volunteers who underwent only diagnostics to confirm the clinical healthy state of the gingiva